| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | ML203 | CTRPv2 | pan-cancer | AAC | -0.0043 | 0.9 |
| mRNA | BRD-K17060750 | CTRPv2 | pan-cancer | AAC | 0.0042 | 0.9 |
| mRNA | PLX4720 | GDSC1000 | pan-cancer | AAC | 0.0034 | 0.9 |
| mRNA | Nilotinib | CCLE | pan-cancer | AAC | -0.0053 | 0.9 |
| mRNA | Bexarotene | FIMM | pan-cancer | AAC | 0.016 | 0.9 |
| mRNA | Zibotentan | GDSC1000 | pan-cancer | AAC | 0.0035 | 0.9 |
| mRNA | Cisplatin | GDSC1000 | pan-cancer | AAC | 0.0036 | 0.9 |
| mRNA | GSK429286A | GDSC1000 | pan-cancer | AAC | -0.0034 | 0.9 |
| mRNA | BRD-M00053801 | CTRPv2 | pan-cancer | AAC | 0.0048 | 0.9 |
| mRNA | VX-11e | GDSC1000 | pan-cancer | AAC | 0.0033 | 0.9 |